SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-246896
Filing Date
2021-08-16
Accepted
2021-08-16 07:12:55
Documents
14
Period of Report
2021-08-16
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d204129d8k.htm   iXBRL 8-K 25026
2 EX-99.1 d204129dex991.htm EX-99.1 57067
6 GRAPHIC g204129g12p62.jpg GRAPHIC 3110
  Complete submission text file 0001193125-21-246896.txt   221537

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cogt-20210816.xsd EX-101.SCH 2894
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cogt-20210816_lab.xml EX-101.LAB 18887
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cogt-20210816_pre.xml EX-101.PRE 11861
7 EXTRACTED XBRL INSTANCE DOCUMENT d204129d8k_htm.xml XML 3472
Mailing Address 200 CAMBRIDGE PARK DRIVE SUITE 3100 CAMBRIDGE MA 02140
Business Address 200 CAMBRIDGE PARK DRIVE SUITE 3100 CAMBRIDGE MA 02140 617-945-5576
Cogent Biosciences, Inc. (Filer) CIK: 0001622229 (see all company filings)

IRS No.: 465308248 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38443 | Film No.: 211174473
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences